Hepatocellular carcinoma (HCC) is the most prevalent and malignant type of liver 
cancer. Besides the high incidence, the resistance to chemotherapy is a major 
problem that leads to the high mortality of HCC. Recently, aberrant expression 
of long noncoding RNAs (lncRNAs) has been considered as a primary feature of 
many types of cancer. However, the genome-wide expression pattern and associated 
functional implications of lncRNAs in chemo-resistant HCC cells remain unknown. 
In this study, we identified 120 differentially expressed lncRNAs with 61 
up-regulated and 59 down-regulated (fold change>2, p<0.05) along with 421 
differentially expressed mRNAs with 228 up-regulated and 193 down-regulated 
(fold change>2, p<0.05) in oxaliplatin-resistant (MHCC97H-OXA) HCC cells, 
compared to parental oxaliplatin-sensitive (MHCC97H) by microarray. The 
underlying pathways were related to cell death, proliferation, cellular response 
to stimulus, including p53 pathway, ErbB pathway and MAPK pathway. Further, 16 
lncRNAs were selected for validation of microarray results with quantitative 
PCR, and a strong correlation was identified between the qPCR results and 
microarray data. We demonstrated for the first time that ENST00000438347, 
NR_073453 and ENST00000502804 were up-regulated in MHCC97H-OXA cells as well as 
chemo-resistant HCC cancerous tissues. Moreover, the expression of 
ENST00000518376 was significantly associated with the tumor size and 
differentiation. Overall survival analysis showed that high expression of 
ENST00000438347 and ENST00000518376 was associated with poor prognosis in HCC 
patients. Taken together, our results reveal that the expression profile in 
oxaliplatin-resistant HCC is significantly altered including lncRNAs. And a 
series of de novo lncRNAs play important functions in HCC oxaliplatin resistance 
and HCC progression.